Compare Cassava Sciences Inc (FLNA) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Zoom Video Communications, Inc. — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Zoom Video Communications, Inc. trades at $97.74 (market cap $27.62B). The key difference: Zoom Video Communications, Inc. is far larger — about 701× Cassava Sciences Inc's market cap, and Zoom Video Communications, Inc. is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Zoom Video Communications, Inc. for 92 Days on average.
| FLNA | ZM | |
|---|---|---|
Market Cap | $39.40M | $27.62B |
Volume | 759,018 | 3,913,188 |
Sector | Health | Technology |
52-Week High | $4.64 | $111.88 |
52-Week Low | $0.68 | $72.72 |
Typical Hold Time | 37 Days | 92 Days |
Enterprise Value | -$43.28M | $20.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 0.26% with a bearish technical signal. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent positive FDA news regarding the clinical hold lift on simufilam for epilepsy research provides a potential catalyst. Cash flow remains negative with net cash flow of -$33.07M in 2025.
The outlook is mixed with strong analyst support (66.7% buy ratings) against fundamental challenges. Investment opportunity lies in clinical trial success, while risks include sustained cash burn and execution hurdles. The stock's low EV/EBITDA of 1.03 and P/B of 0.62 suggest undervaluation if pipeline milestones are met.
Zoom Communications (ZM) trades at $94.67, showing minimal daily movement (-0.11%). The stock maintains a bullish technical outlook with strong moving average signals, though oscillators indicate neutral momentum. Fundamentally, ZM demonstrates robust profitability with 77.3% gross margins and 65.19% net income margin, supported by recent earnings beats. The company continues to innovate with AI-powered revenue solutions and maintains significant institutional interest.
With a consensus price target of $118.08 offering 25% upside potential, ZM presents growth opportunities driven by AI integration and strong financial metrics. However, risks include competitive pressures in the communication software space and reliance on international sales growth. The mixed analyst sentiment (38.78% buy vs 55.1% hold) suggests cautious optimism amid solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
